11 Best Cancer Stocks to Buy Right Now
Cancer remains the second leading cause of death globally, after heart disease.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,743,275 | $2,093,617,028 | +1% | 20.31% |
| 2. | AQR Capital Management Cliff Asness | 8,201,455 | $558,519,093 | +22% | 0.46% |
| 3. | Renaissance Technologies Jim Simons | 3,881,932 | $264,359,569 | +5% | 0.35% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,730,648 | $185,957,129 | +702% | 0.13% |
| 5. | GLG Partners Noam Gottesman | 1,610,670 | $109,686,627 | +53% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | $12,887,302.92 | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | $1,062,243.06 | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | $73,176.91 | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | $6,044.11 | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | $1,805,125.51 | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.81 | 277 | $24,046.37 | 33,200 | 2025-08-15 | Filing | |
| $75.77 | 598 | $45,310.46 | 33,200 | 2025-08-04 | Filing | |
| $67.94 | 3,706 | $251,785.64 | 102,886 | 2025-07-21 | Filing | |
| $68.36 | 1,340 | $91,602.40 | 35,149 | 2025-07-16 | Filing | |
| $68.36 | 983 | $67,197.88 | 40,540 | 2025-07-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,135,393 | $1,371,220,264 | 0.02% | |
| 2. | 17,956,808 | $1,222,858,651 | 0.02% | |
| 3. | 14,595,181 | $993,931,826 | 0.56% | |
| 4. | 9,875,758 | $672,539,120 | 0.03% | |
| 5. | 4,347,731 | $294,898,651 | 0.02% |
News See All
Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight
Incyte Corporation (NASDAQ:INCY) is one of the top most undervalued biotech stocks to buy now.
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Incyte Second Quarter 2025 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties
Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.
10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio
Ray Dalio began his investing journey at just 12 years old and went on to gain experience at institutions such as the New York Stock Exchange, Dominick & Dominick LLC, and Shearson Hayden Stone.
Jim Cramer Highlighted the Top 10 S&P 500 Winners of the Day
“For much of the tremendous run over the past decade, critics love to point out that most of our gains were coming from a small cadre of tech stocks… Over and over again, as the market roared higher...
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy.
Billionaire Hedge Funds
